Titulná stránka
O nás
Kontakt
GDPR
Lekáreň
Portál OUSA
Klienti a pacienti
Odborná verejnosť
Elektronické služby
Prevencia a PZS
Publikácie
Ambulancie na mape
Odborné pracoviská OUSA
Laboratórna medicína v OUSA
Oddelenie klinickej biochémie a imunodiagnostiky
Oddelenie hematológie a transfuziológie
Oddelenie lekárskej genetiky
KONTAKT
Aktuálne oznamy
ŽIADANKY
O nás
Pracovný tím
Ambulancia lekárskej genetiky
Vyšetrenia
Kvalita a certifikáty
Publikácie
Oddelenie klinickej imunológie a alergológie
Oddelenie klinickej farmakológie
Cenník laboratórnych vyšetrení
Žiadanky na vyšetrenia
Etická komisia OÚSA
Veda a výskum
Kvalita a certifikáty
Voľné pozície
Kontakt
Onkologický ústav sv. Alžbety, s.r.o.
Heydukova 10
812 50 Bratislava
+421 2 3224 9111
ousa[at]ousa.sk
Titulná stránka
Odborná verejnosť
Laboratórna medicína ...
Oddelenie lekárskej ...
Publikácie
ODBORNÉ PUBLIKÁCIE (zoznam základných prístupných odborných publikácií zoradených podľa typu analýzy):
BRCA1/2:
Narod, S., A., Foulkes, W., D., 2004: BRCA1 and BRCA2: 1994 and beyond. Nature Rev 4: 665-76. (
PubMed
)
Vasickova, P., Machackova, E., Lukesova, M., Damborsky, J., Horky, O., Pavlu, H., Kuklova, J., Kosinova, V., Navratilova, M., Foretova, L., 2007: High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet 8:32.(
PubMed
)
Welcsh, P., L., Owens, K., N., King, M., C., 2000: Insights into the functions of BRCA1 and BRCA2. Trends Genet 16(2): 69-74.(
PubMed
)
Wagner T.M.U., Hirtenlehner K., Shen P., el all: Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwilde populatins. Hum. Mol. Genetocs, Vol. 8, No. 3, 1999.(
PubMed
)
CDKN2A:
Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group: Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of malanoma. J Med Genet. Jan;43(1):39-47. 2006. (
PubMed
)
Fowler ES, Wolf KS, Chesney TMcC, Schwartzberg LS: Genetic testing for hereditary mealnoma: Controversial, standard of care, or somewhere between the two? Community Oncology March 3:158-161. 2006.(
Link
)
Goldstein AM: Familial Melanoma, Pancreatic Cancer and Germline CDKN2A Mutations.. Human Mutation. 718. 2004. (
PubMed
)
RET:
De Groot JW, Links TP, Plukker JTM, Lips CJM, Hofstra RMW: RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 27(5):535-560. 2006. (
PubMed
)
Baumgartner-Parzer SM. Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W, Vierhapper H: Polymorphisms in exon 13 and intron 14 of RET protooncogene: Genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90(11):6232-6236. 2005. (
PubMed
)
KRAS:
Benvenuti S, Sartore-Bianchi A, di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67(6):2643-2648. 2007. (
PubMed
)
Van Krieken JHJM, Jung A, Kirchner T et al.: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417-431. 2008. (
PubMed
)
BRAF:
Nikiforov YE: thyroid carcinoma: molecular pathways and therapeutic targets. Modern pathology 21:S37-S43. 2008. (
PubMed
)
Elisei R, Ugolini C, Viola D, Lupi C et al: BRAF V600E mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin endocrine Metab 93(10):3943-3949. 2008. (
PubMed
)
HPV genotyp:
Meijer CHJ, Snijders PJ, Castle PE: Clinical utility of HPV genotyping. Gynecologic Oncology 103: 12-17. 2006. (
PubMed
)
Barzon L, Giorgi C, Buonaguro FM, Palú G: Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infectious Agents and Cancer 3:14 doi:10.1186/1750-9378-3-142008, 2008. (
PubMed
)
HPV expresia:
Weismann P, Weismanova E, Masak L a kol.: The detection of circulating tumor cells expressing E6/E7 HR-HPV oncogenes in peripheral blood in cervical cancer patients. NEOPLASMA 2009, 56(3);230-238. (
PubMed
)
Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 17(10):2536-45, 2008. (
PubMed
)
MDR:
Liu Y, Peng H, Zhang J-T: Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol 68(2):430-438, 2005. (
PubMed
)
Gillet JP, Gottesman MM: Mechanisms of Multidrug Resistance in Cancer in Multi-Drug Resistance in Cancer, Methods in Molecular Biology, vol. 596, Humana Press, a part of Springer Science + Business Media, LLC 2010. (
PubMed
))